Han and colleagues described a clinical case of a patient with metastatic refractory melanoma that acquired resistance to anti-PD-1 immunotherapy and exhibited enhanced expression of IL-34 in refractory melanoma tissues [82]. Here, PDCD1 is linked to melanoma.